CANCIDAS PACKAGE INSERT PDF

drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.

Author: Faubar Akizil
Country: Gabon
Language: English (Spanish)
Genre: Medical
Published (Last): 17 September 2008
Pages: 22
PDF File Size: 4.43 Mb
ePub File Size: 8.91 Mb
ISBN: 530-5-89969-430-1
Downloads: 41973
Price: Free* [*Free Regsitration Required]
Uploader: Duzilkree

Chemical degradation leads to the formation of the metabolite L and very low levels of reactive intermediates. Caspofungin does not interact substantially with the cytochrome P enzyme system, but does undergo significant hepatic metabolism.

Animal studies reveal distribution primarily into the liver and kidneys. No dosage adjustment is needed in patients with renal impairment. The following organisms are generally considered susceptible to caspofungin in vitro: Although specific neonatal recommendations are not available, clinical practice guidelines suggest caspofungin as salvage therapy.

Caspofungin Acetate for Injection Now Available from Fresenius Kabi

Dilution Add appropriate dose to mL of 0. Microbiology Mechanism of Action Caspofungin acetate, an echinocandin, is an antifungal agent. Infants 3 months and older, Children, and Adolescents.

Caution is advised when administering to nursing mothers. Related Drug Information Drug Summary. Please see the full prescribing information for Caspofungin Acetate for Injection, including boxed warning, at http: Administering inducers of hepatic cytochrome P, such as nevirapine, concurrently with caspofungin may reduce the plasma concentrations of caspofungin.

  ART COMPUTER VIRUS RESEARCH DEFENSE PETER SZOR PDF

These mutations are associated with higher MICs and breakthrough infection. The final diluted infusion may be stored for up to 24 hours at 25 degrees C or less 77 degrees F or lessor for up to 48 hours inesrt refrigeration at 2 to 8 degrees C.

Some experts suggest that if an echinocandin is used in neonates, micafungin is the preferred agent.

Cancidas (caspofungin acetate) dose, indications, adverse effects, interactions from

Studies to evaluate the effects of exposure on a breast-fed infant have not been conducted; however, based on caspofungin’s poor oral absorption, the risks appear to be low. Cyclosporine concentrations are not altered by coadministration with caspofungin.

A local search option of this data can be found here. Recommended in patients with persistent or recurrent fever after 4 to 7 days of antibiotics and anticipated neutropenia duration more than 7 days. Isnert general, antifungal therapy should continue for at least 14 days after the last positive culture.

Treat for at least 8 weeks with duration dependent on extent and length of immunosuppression, infection site, and disease improvement. Do not mix or co-infuse caspofungin with other medications or infuse with dextrose-containing solutions.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

  GLISSANT CARIBBEAN DISCOURSE PDF

Clinical practice guidelines suggest caspofungin as an alternative to posaconazole for aspergillosis prophylaxis in high-risk patients i. The risk of relapse is greater in HIV-infected patients for esophageal candidiasis, and suppressive antifungal therapy may be considered after a course of treatment.

The pharmacokinetic parameters of caspofungin are not altered by tacrolimus. The final phase half-life of 40—50 hours results in significant tissue distribution. Monitor patients who develop abnormal liver function tests LFTs during concomitant use with Caspofungin. Important Safety Information Caspofungin is contraindicated in patients with known hypersensitivity to any component of this product. Administering inducers of hepatic cytochrome P, such as efavirenz, concurrently with caspofungin may reduce the plasma concentrations of caspofungin.

There is little excretion or biotransformation during the first 30 hours post-infusion. For fluid restricted patients, may dilute dose to a final concentration not to exceed 0. According to the manufacturer, drugs that may lead to reductions in caspofungin concentrations include carbamazepine. Distribution, the primary mechanism influencing plasma clearance, follows a three-compartment model.

Mix gently until the solution is clear.